{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:43:23Z","timestamp":1783089803234,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82071480"],"award-info":[{"award-number":["82071480"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2021YFC2501800"],"award-info":[{"award-number":["2021YFC2501800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This single-center study aimed to determine the effective dose and safety of remimazolam besylate for the sedation of postoperative patients undergoing invasive mechanical ventilation in the intensive care unit (ICU). Mechanically ventilated patients admitted to the ICU after surgery were included. The Narcotrend index (NTI) was used to assess the depth of sedation, and the Richmond Agitation-Sedation Scale (RASS) score was also recorded. Remimazolam besylate was administered initially at a loading dose of 0.02\u00a0mg\/kg, followed by a gradual increase of 0.005\u00a0mg\/kg each time until the targeted depth of sedation was achieved (NTI 65\u201394). A maintenance dose of remimazolam besylate was administered starting at 0.2\u00a0mg\/kg\/h, followed by increments or subtractions of 0.05\u00a0mg\/kg\/h each time until a satisfactory depth of sedation was achieved and maintained for at least 30\u00a0min. The demographic data, anesthesia, surgery types, hemodynamics and respiratory parameters were recorded. Adverse events and adverse drug reactions were monitored for safety. Twenty-three patients were eventually included in this study covering a period of 1\u00a0year. A satisfactory depth of sedation was achieved by a single intravenous infusion of remimazolam besylate at a loading dose of 0.02\u20130.05\u00a0mg\/kg followed by a maintenance dose of 0.20\u20130.35\u00a0mg\/kg\/h. There were no significant changes in hemodynamic and respiratory parameters within 10\u00a0min after the administration of remimazolam besylate. In addition, a significant correlation was observed between the NTI and the RASS score for assessing sedation (r\u2009=\u20090.721, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The NTI showed a predictive probability for a RASS score of 0.817. Remimazolam besylate was effective for mild\/moderate sedation of invasively mechanically ventilated postoperative patients in the ICU while maintaining excellent respiratory and hemodynamic stability. The NTI can be used as a good tool for the objective evaluation of the depth of sedation and agitation.<\/jats:p>","DOI":"10.1038\/s41598-022-20946-6","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T21:03:03Z","timestamp":1667941383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Remimazolam besylate for the sedation of postoperative patients undergoing invasive mechanical ventilation in the ICU: a prospective dose\u2012response study"],"prefix":"10.1038","volume":"12","author":[{"given":"Xiaoyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"9","key":"20946_CR1","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","volume":"46","author":"JW Devlin","year":"2018","unstructured":"Devlin, J. W. et al. Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit. Care Med. 46(9), e825\u2013e873 (2018).","journal-title":"Crit. Care Med."},{"issue":"4","key":"20946_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00023210-200317040-00003","volume":"17","author":"K McKeage","year":"2003","unstructured":"McKeage, K. & Perry, C. M. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 17(4), 235\u2013272 (2003).","journal-title":"CNS Drugs"},{"issue":"29","key":"20946_CR3","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.2174\/1381612043382846","volume":"10","author":"PE Marik","year":"2004","unstructured":"Marik, P. E. Propofol: Therapeutic indications and side-effects. Curr. Pharm. Des. 10(29), 3639\u20133649 (2004).","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"20946_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1592\/phco.27.3.389","volume":"27","author":"SP Spina","year":"2007","unstructured":"Spina, S. P. & Ensom, M. H. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 27(3), 389\u2013398 (2007).","journal-title":"Pharmacotherapy"},{"issue":"1","key":"20946_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0885066614538749","volume":"31","author":"LM Pulak","year":"2016","unstructured":"Pulak, L. M. & Jensen, L. Sleep in the Intensive Care Unit: A review. J. Intensive Care Med. 31(1), 14\u201323 (2016).","journal-title":"J. Intensive Care Med."},{"issue":"6","key":"20946_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/00000542-199212000-00013","volume":"77","author":"JP Belleville","year":"1992","unstructured":"Belleville, J. P., Ward, D. S., Bloor, B. C. & Maze, M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 77(6), 1125\u20131133 (1992).","journal-title":"Anesthesiology"},{"issue":"12","key":"20946_CR7","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00134-004-2417-z","volume":"30","author":"Y Shehabi","year":"2004","unstructured":"Shehabi, Y., Ruettimann, U., Adamson, H., Innes, R. & Ickeringill, M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: Sedative and cardiovascular effects. Intensive Care Med. 30(12), 2188\u20132196 (2004).","journal-title":"Intensive Care Med."},{"issue":"6","key":"20946_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-020-01299-8","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam, S. J. Remimazolam: First approval. Drugs 80(6), 625\u2013633 (2020).","journal-title":"Drugs"},{"issue":"1","key":"20946_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","volume":"107","author":"GJ Kilpatrick","year":"2007","unstructured":"Kilpatrick, G. J. et al. CNS 7056: A novel ultra-short-acting benzodiazepine. Anesthesiology 107(1), 60\u201366 (2007).","journal-title":"Anesthesiology"},{"key":"20946_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.739603","volume":"12","author":"XL Liu","year":"2021","unstructured":"Liu, X. L. et al. Remimazolam protects against LPS-induced endotoxicity improving survival of endotoxemia mice. Front. Pharmacol. 12, 739603 (2021).","journal-title":"Front. Pharmacol."},{"issue":"Pt B","key":"20946_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108331","volume":"101","author":"HH Fang","year":"2021","unstructured":"Fang, H. H. et al. Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages. Int. Immunopharmacol. 101(Pt B), 108331 (2021).","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"20946_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bpa.2005.08.010","volume":"20","author":"S Kreuer","year":"2006","unstructured":"Kreuer, S. & Wilhelm, W. The narcotrend monitor. Best Pract. Res. Clin. Anaesthesiol. 20(1), 111\u2013119 (2006).","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"issue":"2","key":"20946_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1213\/01.ANE.0000157565.00359.E2","volume":"101","author":"S Kreuer","year":"2005","unstructured":"Kreuer, S. et al. Narcotrend or bispectral index monitoring during desflurane-remifentanil anesthesia: A comparison with a standard practice protocol. Anesth. Analg. 101(2), 427\u2013434 (2005).","journal-title":"Anesth. Analg."},{"issue":"3","key":"20946_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1213\/01.ANE.0000103182.78466.EF","volume":"98","author":"S Kreuer","year":"2004","unstructured":"Kreuer, S., Wilhelm, W., Grundmann, U., Larsen, R. & Bruhn, J. Narcotrend index versus bispectral index as electroencephalogram measures of anesthetic drug effect during propofol anesthesia. Anesth. Analg. 98(3), 692\u2013697 (2004).","journal-title":"Anesth. Analg."},{"issue":"5","key":"20946_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/bja\/aem231","volume":"99","author":"I Rundshagen","year":"2007","unstructured":"Rundshagen, I. et al. Narcotrend-assisted propofol\/remifentanil anaesthesia vs clinical practice: Does it make a difference?. Br. J. Anaesth. 99(5), 686\u2013693 (2007).","journal-title":"Br. J. Anaesth."},{"issue":"22","key":"20946_CR16","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1001\/jama.289.22.2983","volume":"289","author":"EW Ely","year":"2003","unstructured":"Ely, E. W. et al. Monitoring sedation status over time in ICU patients: Reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 289(22), 2983\u20132991 (2003).","journal-title":"JAMA"},{"issue":"1","key":"20946_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00000542-199601000-00005","volume":"84","author":"WD Smith","year":"1996","unstructured":"Smith, W. D., Dutton, R. C. & Smith, N. T. Measuring the performance of anesthetic depth indicators. Anesthesiology 84(1), 38\u201351 (1996).","journal-title":"Anesthesiology"},{"issue":"1","key":"20946_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","volume":"41","author":"J Barr","year":"2013","unstructured":"Barr, J. et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit. Care Med. 41(1), 263\u2013306 (2013).","journal-title":"Crit. Care Med."},{"issue":"3","key":"20946_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","volume":"127","author":"T St\u00f6hr","year":"2021","unstructured":"St\u00f6hr, T. et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br. J. Anaesth. 127(3), 415\u2013423 (2021).","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"20946_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/17512433.2021.1901575","volume":"14","author":"W Chen","year":"2021","unstructured":"Chen, W., Chen, S. & Huang, Y. Induction and maintenance of procedural sedation in adults: Focus on remimazolam injection. Expert Rev. Clin. Pharmacol. 14(4), 411\u2013426 (2021).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"20946_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00228-019-02800-3","volume":"76","author":"XY Sheng","year":"2020","unstructured":"Sheng, X. Y. et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur. J. Clin. Pharmacol. 76(3), 383\u2013391 (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"20946_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.chest.2018.09.015","volume":"155","author":"NJ Pastis","year":"2019","unstructured":"Pastis, N. J. et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 155(1), 137\u2013146 (2019).","journal-title":"Chest"},{"issue":"3","key":"20946_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.gie.2018.04.2351","volume":"88","author":"DK Rex","year":"2018","unstructured":"Rex, D. K. et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest. Endosc. 88(3), 427-37e6 (2018).","journal-title":"Gastrointest. Endosc."},{"issue":"4","key":"20946_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1213\/ANE.0000000000000548","volume":"120","author":"KM Borkett","year":"2015","unstructured":"Borkett, K. M. et al. A phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth. Analg. 120(4), 771\u2013780 (2015).","journal-title":"Anesth. Analg."},{"key":"20946_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109899","volume":"66","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Population pharmacokinetic\/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J. Clin. Anesth. 66, 109899 (2020).","journal-title":"J. Clin. Anesth."},{"issue":"4","key":"20946_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00540-020-02788-6","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi, M. et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: A multicenter, single-blind, randomized, parallel-group, phase IIb\/III trial. J. Anesth. 34(4), 543\u2013553 (2020).","journal-title":"J. Anesth."},{"issue":"4","key":"20946_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00540-020-02776-w","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi, M. et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): Results of a multicenter, randomized, double-blind, parallel-group comparative trial. J. Anesth. 34(4), 491\u2013501 (2020).","journal-title":"J. Anesth."},{"issue":"1","key":"20946_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00000542-200307000-00009","volume":"99","author":"S Kreuer","year":"2003","unstructured":"Kreuer, S., Biedler, A., Larsen, R., Altmann, S. & Wilhelm, W. Narcotrend monitoring allows faster emergence and a reduction of drug consumption in propofol-remifentanil anesthesia. Anesthesiology 99(1), 34\u201341 (2003).","journal-title":"Anesthesiology"},{"issue":"4","key":"20946_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/ALN.0000000000003103","volume":"132","author":"J Sch\u00fcttler","year":"2020","unstructured":"Sch\u00fcttler, J. et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 132(4), 652\u2013666 (2020).","journal-title":"Anesthesiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20946-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20946-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20946-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T21:07:55Z","timestamp":1667941675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20946-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20946"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20946-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"21 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19022"}}